kanjinti.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Sitemap: | ||
Meta Tags
| Title | Herceptin® Biosimilar | KANJINTI® (trastuzumab-anns) for |
| Description | AMGEN HELPS YOU TAKE ON MANY ASPECTS OF PATIENT Find out more about KANJINTI® (trastuzumab-anns), a Herceptin® biosimilar. See Important Safety Information including Boxed |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 44.233.208.9 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
kanjinti.com Valuation
|
US$4,320,715
Last updated: 2023-04-27 03:38:48
kanjinti.com has Semrush global rank of 2,449,665. kanjinti.com has an estimated worth of US$ 4,320,715, based on its estimated Ads revenue. kanjinti.com receives approximately 498,544 unique visitors each day. Its web server is located in United States, with IP address 44.233.208.9. According to SiteAdvisor, kanjinti.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$4,320,715 |
| Daily Ads Revenue | US$3,989 |
| Monthly Ads Revenue | US$119,651 |
| Yearly Ads Revenue | US$1,435,807 |
| Daily Unique Visitors | 33,237 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| kanjinti.com. | A | 300 | IP: 44.233.208.9 |
| kanjinti.com. | A | 300 | IP: 52.38.168.248 |
| kanjinti.com. | NS | 86400 | NS Record: ns-117.awsdns-14.com. |
| kanjinti.com. | NS | 86400 | NS Record: ns-1319.awsdns-36.org. |
| kanjinti.com. | NS | 86400 | NS Record: ns-1995.awsdns-57.co.uk. |
| kanjinti.com. | NS | 86400 | NS Record: ns-604.awsdns-11.net. |
| kanjinti.com. | MX | 300 | MX Record: 20 a-0018ee01.gslb.pphosted.com. |
| kanjinti.com. | MX | 300 | MX Record: 10 a-0018ee01.gslb.pphosted.com. |
HtmlToTextCheckTime:2023-04-27 03:38:48
| Indications Adjuvant Breast Cancer KANJINTI® is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*) … Read more breast cancer: KANJINTI® is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*) breast cancer … Read more : As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel As part of treatment with docetaxel and carboplatin As a single agent following multi-modality anthracycline-based therapy Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product. * High-risk is defined as ER/PR positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3. Metastatic Breast Cancer KANJINTI® is indicated: In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic |
HTTP Headers
HTTP/1.1 403 Forbidden Server: awselb/2.0 Date: Wed, 20 Oct 2021 11:00:25 GMT Content-Type: text/html Content-Length: 118 Connection: keep-alive |
kanjinti.com Whois Information
Domain Name: KANJINTI.COM Registry Domain ID: 2056828450_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2018-10-05T16:35:21Z Creation Date: 2016-09-02T16:30:36Z Registry Expiry Date: 2023-09-02T16:30:36Z Registrar: MarkMonitor Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2083895740 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS-117.AWSDNS-14.COM Name Server: NS-1319.AWSDNS-36.ORG Name Server: NS-1995.AWSDNS-57.CO.UK Name Server: NS-604.AWSDNS-11.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-08T23:56:19Z <<< |